---
agent_readiness:
  band: human-only
  dimensions:
    agent_card: false
    agent_skills: false
    agentic_access: false
    auth_clarity: false
    consent_identity: false
    dry_run_mode: false
    error_semantics: false
    event_surface_described: false
    idempotency: false
    mcp_server: false
    openapi_examples: false
    rate_limit_signal: false
    reversibility_documented: false
    spec_presence: false
    well_known_catalog: false
  schema_version: 0.2
  score: 0.0
  scored_at: '2026-08-19'
api_count: 0
artifact_total: 1
common:
- group: company
  title: ''
  type: Website
  url: https://www.quralis.com/
- group: company
  title: ''
  type: About
  url: https://www.quralis.com/our-story/
- group: other
  title: ''
  type: Pipeline
  url: https://www.quralis.com/pipeline/
- group: other
  title: ''
  type: Platform
  url: https://www.quralis.com/platforms/
- group: other
  title: ''
  type: Team
  url: https://www.quralis.com/people/
- group: company
  title: ''
  type: Careers
  url: https://www.quralis.com/culture/
- group: other
  title: ''
  type: Patients
  url: https://www.quralis.com/patients/
- group: other
  title: ''
  type: Publications
  url: https://www.quralis.com/presentations-and-publications/
- group: company
  title: ''
  type: News
  url: https://www.quralis.com/news/
- group: company
  title: ''
  type: Blog
  url: https://www.quralis.com/news/
- group: operate
  title: ''
  type: Support
  url: https://www.quralis.com/contact/
- group: commercial
  title: ''
  type: PrivacyPolicy
  url: https://www.quralis.com/privacy-policy/
- group: commercial
  title: ''
  type: TermsOfService
  url: https://www.quralis.com/terms-of-use/
- group: company
  title: ''
  type: LinkedIn
  url: https://www.linkedin.com/company/quralis1/
- group: company
  title: ''
  type: Twitter
  url: https://twitter.com/QurAlisCo
- group: other
  title: ''
  type: SecondaryMarket
  url: https://forgeglobal.com/quralis_stock/
- group: auth
  title: ''
  type: DomainSecurity
  url: security/quralis-domain-security.yml
- group: agent
  title: ''
  type: WellKnown
  url: well-known/quralis-well-known.yml
- group: agent
  title: ''
  type: LLMsTxt
  url: llms/quralis-llms.txt
coverage:
  checked: '2026-08-05'
  detail: QurAlis is a clinical-stage biopharmaceutical company whose product is a drug pipeline, not software — no api., developer., docs., portal. or data. host resolves for quralis.com, no quralis GitHub organisation or npm/PyPI package exists, and every /.well-known/ and spec path on www.quralis.com returns a clean 404, leaving only the marketing site's WordPress /wp-json/ CMS routes whose bundled MCP and Abilities endpoints answer anonymous callers with 401 rest_forbidden.
  evidence:
  - status: 404
    url: https://www.quralis.com/openapi.json
  - status: 404
    url: https://www.quralis.com/.well-known/agent-card.json
  - status: 404
    url: https://www.quralis.com/llms.txt
  - status: 401
    url: https://www.quralis.com/wp-json/mcp/mcp-adapter-default-server
  - status: 404
    url: https://api.github.com/orgs/quralis
  reason: not-a-software-company
  state: none
created: '2026-08-05'
description: 'QurAlis Corporation is a clinical-stage biotechnology company founded on December 12, 2016 in Cambridge, Massachusetts by Drs. Kasper Roet, Kevin Eggan and Clifford Woolf together with Q-State Biosciences, and staffed by neurodegenerative biologists out of Harvard Medical School and Harvard University. The company develops precision medicines for amyotrophic lateral sclerosis (ALS), frontotemporal dementia (FTD) and other neurodegenerative and neurological diseases, built on the discovery — published in Nature Neuroscience by co-founder Kevin Eggan''s lab — that loss of normal TDP-43 function drives a decrease in STATHMIN-2 (STMN2) expression and impairs neuronal repair. Its lead candidates are QRL-201, a first-in-class molecule intended to restore STMN2 expression in ALS (ANQUR trial), and QRL-101, a potentially best-in-class selective Kv7.2/7.3 ion channel opener for hyperexcitability-induced disease progression in ALS as well as epilepsy and pain; a third program targets
  UNC13A cryptic-exon mis-splicing. Therapies are built on the proprietary FlexASO® anti-sense oligonucleotide splice-modulator platform. QurAlis publishes a corporate site covering its story, pipeline, platform, people, patient resources, presentations and press releases, but runs no developer program: no API documentation, no SDKs, no developer portal, no GitHub organisation and no machine-readable API contract of any kind.'
image: https://www.quralis.com/wp-content/uploads/2024/04/Quralis_Square_ogThumbnail_Royal_Blue_RGB.png
layout: provider
modified: '2026-08-05'
name: QurAlis
nav: Providers
network: true
overview: 'QurAlis is profiled on the [APIs.io](https://apis.io/) network. Tagged areas include Company, Biotechnology, Pharmaceuticals, Life Sciences, and Neurology.


  QurAlis'' developer surface includes product news, engineering blog, support, and 16 more developer resources.'
random_paper: 24
score:
  band: emerging
  composite: 11.2
  delta: -1.0
  facets:
    access_clarity: 21.1
    commercial_clarity: 21.1
    contract_governance: 0.0
    contract_quality: 0.0
    developer_ergonomics: 7.1
    discoverability: 57.4
    governance: 0.0
    operational_transparency: 0.0
  previous_composite: 12.2
  regulatory:
    applies: true
    matched_via: tags
    regime: Health
    regime_id: health
    score: 17.5
  schema_version: 0.12.0
  scored_at: '2026-08-19'
  trend: flat
security:
- kind: domain-security
  name: Quralis Domain Security
  slug: quralis-domain-security
  summary_line: TLSv1.3 · DMARC
slug: quralis
tags:
- Company
- Biotechnology
- Pharmaceuticals
- Life Sciences
- Neurology
- Neurodegenerative Disease
- ALS
- Precision Medicine
- Clinical Trials
- Drug Development
- Healthcare
website: https://www.quralis.com/
---
